perinatologyРоссийский вестник перинатологии и педиатрииRossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)1027-40652500-2228Ltd. “The National Academy of Pediatric Science and Innovation”10.21508/1027-4065-2016-61-5-149-154perinatology-398Research ArticleXIII РОССИЙСКАЯ КОНФЕРЕНЦИЯ «ПЕДИАТРИЯ И ДЕТСКАЯ ХИРУРГИЯ В ПРИВОЛЖСКОМ ФЕДЕРАЛЬНОМ ОКРУГЕ»13TH RUSSIAN CONFERENCE ON PEDIATRICS AND PEDIATRIC SURGERY IN THE VOLGA FEDERAL DISTRICTПортопульмональная гипертензия у ребенкаPortopulmonary hypertension in a childСадыковаД. И.SadykovaD. I.

кафедра педиатрии с курсом поликлинической педиатрии 

д.м.н., проф., зав. кафедрой

420012 Казань, ул. Муштари, д. 11

СабироваД. Р.SabirovaD. R.

кафедра педиатрии с курсом поликлинической педиатрии

к.м.н., асс. кафедры

420012 Казань, ул. Муштари, д. 11

ШакироваА. Р.ShakirovaA. R.

кафедра педиатрии с курсом поликлинической педиатрии

асс. кафедры

420012 Казань, ул. Муштари, д. 11

ФирсоваН. Н.FirsovaN. N.

кардиологическое отделение

зав. отделением

420138 Казань, Оренбургский тракт, д. 140

ХуснуллинаГ. А.KhusnullinaG. A.

кардиологическое отделение

к.м.н., врач отделения

КустоваН. В.KustovaN. V.

кафедра педиатрии с курсом поликлинической педиатрии

врач-интерн кафедры

ГБОУ ДПО «Казанская государственная медицинская академия» Минздрава РоссииРоссияKazan State Medical Academy, Ministry of Health of RussiaRussian FederationГАУЗ «Детская республиканская клиническая больница» Министерства Здравоохранения Республики Татарстан», КазаньРоссияRepublican Children`s Clinical Hospital, Ministry of Health of the Republic of Tatarstan, KazanRussian Federation201620112016615149154Copyright © Ltd. “The National Academy of Pediatric Science and Innovation”, 20162016Ltd. “The National Academy of Pediatric Science and Innovation”Ltd. “The National Academy of Pediatric Science and Innovation”https://www.ped-perinatology.ru/jour/about/submissions#copyrightNoticehttps://www.ped-perinatology.ru/jour/article/view/398

Статья посвящена проблеме портопульмональной гипертензии (легочная артериальная гипертензия, связанная с портальной гипертензией). Легочная гипертензия является редким, прогностически неблагоприятным осложнением портальной гипертензии, независимо от этиологического фактора последней. Диагностическими критериями портопульмональной гипертензии являются: наличие портальной гипертензии с или без заболевания печени, среднее давление в легочной артерии более 25 мм рт. ст. в покое, нормальные показатели давления заклинивания в легочной артерии (<15 мм рт. ст), легочное сосудистое сопротивление более 3 ед. Вуда/м2. Цель работы: описание развития клинической картины, диагностики и лечения портопульмональной гипертензии у больного на фоне корригированной портальной гипертензии. Существуют трудности в постановке диагноза портопульмональной гипертензии, так как ее симптомы неспецифичны. Наиболее характерные признаки — одышка, утомляемость, снижение толерантности к физической нагрузке, синкопальные состояния.

The paper deals with portopulmonary hypertension (pulmonary arterial hypertension associated with portal hypertension). Pulmonary hypertension is a rare, prognostically unfavorable complication of portal hypertension, regardless of the etiological factor of the latter. The diagnostic criteria for portopulmonary hypertension are portal hypertension with or without liver disease; a resting mean pulmonary artery pressure >25 mm Hg; a normal pulmonary artery wedge pressure <15 mm Hg; and a pulmonary vascular resistance of more than 3 Wood units/m2. Objective: to describe of the development of the clinical picture, diagnosis, and treatment of portopulmonary hypertension in a patient during corrected portal hypertension. There are challenges in the diagnosis of portopulmonary hypertension because its symptoms are nonspecific. The most characteristic symptoms of the disease are dyspnea, fatigue, exercise intolerance, and syncope.

детилегочная артериальная гипертензияпортопульмональная гипертензияантагонисты эндотелиновых рецепторовингибиторы фосфодиэстеразы-5childrenpulmonary arterial hypertensionportopulmonary hypertensionendothelin receptor antagonistsphosphodiesterase 5 inhibitorsReferencesGaliè N., Humbert M., Vachiery J.L. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 4: 903–975.Galiè N., Humbert M., Vachiery J.L. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 4: 903–975.Galie N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology and the European Respiratory Society, endorsed by the International Society of Heart and Lung Transplantation. Eur Heart J 2009; 30: 20: 2493–2537.Galie N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology and the European Respiratory Society, endorsed by the International Society of Heart and Lung Transplantation. Eur Heart J 2009; 30: 20: 2493–2537.Simonneau G., Gatzoulis M.A., Adatia I. et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D34 — D41.Simonneau G., Gatzoulis M.A., Adatia I. et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D34 — D41.Руководство по легочной гипертензии у детей. Под ред. Л.A. Бокерия, С.В. Горбачевского, М.А. Школьниковой. М 2013; 416. 416 (Guidelines for pulmonary hypertension in children. L.A. Bokeriya, S.V. Gorbachevskij, M.А. Shkol’nikova (eds). Moscow 2013; 416. (in Russ))Руководство по легочной гипертензии у детей. Под ред. Л.A. Бокерия, С.В. Горбачевского, М.А. Школьниковой. М 2013; 416. 416 (Guidelines for pulmonary hypertension in children. L.A. Bokeriya, S.V. Gorbachevskij, M.А. Shkol’nikova (eds). Moscow 2013; 416. (in Russ))Krowka M.J., Miller D.P., Barst R.J. et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest 2012; 141: 906–915.Krowka M.J., Miller D.P., Barst R.J. et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest 2012; 141: 906–915.Humbert M., Sitbon O., Chaouat A. et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023–1030.Humbert M., Sitbon O., Chaouat A. et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023–1030.Herve P., Lebrec D., Brenot F. et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998; 11: 1153–1166.Herve P., Lebrec D., Brenot F. et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998; 11: 1153–1166.Hoeper M.M., Krowka M.J., Strassburg C.P. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363: 1461–1468.Hoeper M.M., Krowka M.J., Strassburg C.P. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363: 1461–1468.Colle I.O., Moreau R., Godinho E. et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37: 401–409.Colle I.O., Moreau R., Godinho E. et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37: 401–409.Kochar R., Nevah R., Rubin M.I. et al. Pulmonary complications of cirrhosis. Curr Gastroenterol Rep 2011; 13: 34–39.Kochar R., Nevah R., Rubin M.I. et al. Pulmonary complications of cirrhosis. Curr Gastroenterol Rep 2011; 13: 34–39.Swanson K.L., Wiesner R.H., Nyberg S.L. et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008; 8: 2445–2453.Swanson K.L., Wiesner R.H., Nyberg S.L. et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008; 8: 2445–2453.Гурьянов В.А., Толмачев Г.Н. Первичная (идиопатическая) легочная гипертензия (синдром Арриллага — Аэрза) и беременность — интенсивная терапия и анестезия. Анестезиол и реаниматол 2014; 6: 56–58. (Gur’yanov V.А., Tolmachev G.N. Primary (idiopathic) pulmonary hypertension (Arrillaga — Aerza syndrome) and pregnancy — intensive care and anesthesia. Anesteziol reanimatol 2014; 6: 56–58. (in Russ))Гурьянов В.А., Толмачев Г.Н. Первичная (идиопатическая) легочная гипертензия (синдром Арриллага — Аэрза) и беременность — интенсивная терапия и анестезия. Анестезиол и реаниматол 2014; 6: 56–58. (Gur’yanov V.А., Tolmachev G.N. Primary (idiopathic) pulmonary hypertension (Arrillaga — Aerza syndrome) and pregnancy — intensive care and anesthesia. Anesteziol reanimatol 2014; 6: 56–58. (in Russ))Roberts K.E., Fallon M.B., Krowka M.J. et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009; 179: 835–842.Roberts K.E., Fallon M.B., Krowka M.J. et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009; 179: 835–842.Golbin J.M., Krowka M.J. Portopulmonary hypertension. Ann Thorac Med 2010; 5: 1: 5–9.Golbin J.M., Krowka M.J. Portopulmonary hypertension. Ann Thorac Med 2010; 5: 1: 5–9.Krowka M.J., Swanson K.L., Frantz R.P. et al. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006; 44: 1502–1510.Krowka M.J., Swanson K.L., Frantz R.P. et al. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006; 44: 1502–1510.Kawut S.M., Krowka M.J., Trotter J.F. et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008; 48: 196–203.Kawut S.M., Krowka M.J., Trotter J.F. et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008; 48: 196–203.Le Pavec J., Souza R., Herve P. et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 2008; 178: 637–643.Le Pavec J., Souza R., Herve P. et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 2008; 178: 637–643.Halank M., Knudsen L., Seyfarth H.J. et al. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. Z Gastroenterol 2011; 49: 1258– 1262.Halank M., Knudsen L., Seyfarth H.J. et al. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. Z Gastroenterol 2011; 49: 1258– 1262.Porres-Aguilar M., Zuckerman M.J., Figueroa-Casas J.B. et al. Portopulmonary hypertension: state of the art. Ann Hepatol 2008; 49: 1258–1262.Porres-Aguilar M., Zuckerman M.J., Figueroa-Casas J.B. et al. Portopulmonary hypertension: state of the art. Ann Hepatol 2008; 49: 1258–1262.Cohn J.N. Optimal diuretic therapy for heart failure. Am J Med 2001; 111: 7: 577.Cohn J.N. Optimal diuretic therapy for heart failure. Am J Med 2001; 111: 7: 577.Galie N., Olschewski H., Oudiz R.J. et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the amrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (APIES) study 1 and 2. Circulation 2008; 117: 3010– 3019.Galie N., Olschewski H., Oudiz R.J. et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the amrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (APIES) study 1 and 2. Circulation 2008; 117: 3010– 3019.Galie N., Rubin U., Hoeper M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 2008; 371: 2093–2100.Galie N., Rubin U., Hoeper M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 2008; 371: 2093–2100.Inohara T., Niwa K., Yao A. Survey of the current status and management of Eisenmenger syndrome: A Japanese nationwide survey. J Cardiol 2014;63: 286–290.Inohara T., Niwa K., Yao A. Survey of the current status and management of Eisenmenger syndrome: A Japanese nationwide survey. J Cardiol 2014;63: 286–290.Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. Curr Vasc Pharmacol 2009; 7: 225–233.Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. Curr Vasc Pharmacol 2009; 7: 225–233.Beghetti M., Haworth S.G., Bonnet D. et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol 2009; 68: 948–955.Beghetti M., Haworth S.G., Bonnet D. et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol 2009; 68: 948–955.Чазова И.Е., Черняская А.М., Мартынюк Т.В. и др. Актуальные вопросы хронической тромбоэмболической легочной гипертензии: мнения экспертов. Кардиол вестн 2015; 1: 78–79. (Chazova I.E., Chernyaskaya А.M., Martynyuk T.V. et al. Topical issues of chronic thromboembolic pulmonary hypertension: expert opinions. Kardiol vestn 2015; 1: 78–79. (in Russ))Чазова И.Е., Черняская А.М., Мартынюк Т.В. и др. Актуальные вопросы хронической тромбоэмболической легочной гипертензии: мнения экспертов. Кардиол вестн 2015; 1: 78–79. (Chazova I.E., Chernyaskaya А.M., Martynyuk T.V. et al. Topical issues of chronic thromboembolic pulmonary hypertension: expert opinions. Kardiol vestn 2015; 1: 78–79. (in Russ))

The authors declare that there are no conflicts of interest present.